Journal articles on the topic 'Open Forum Speakers Bureau'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Open Forum Speakers Bureau.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Emanuel, Robyn M., Zhenya Senyak, Archie McCallister, Mary Cotter, Barbara VanHusen, Claire N. Harrison, and Ruben A. Mesa. "The MPN Fatigue Project: Stage 1 Results Of The MPN Forum Internet-Based Survey Among 879 MPN Patients." Blood 122, no. 21 (November 15, 2013): 1595. http://dx.doi.org/10.1182/blood.v122.21.1595.1595.
Full textBaljevic, Muhamed, Cristina Gasparetto, Gary J. Schiller, Sascha A. Tuchman, Natalie S. Callander, Suzanne Lentzsch, Jorge Monge, et al. "Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment." Blood 138, Supplement 1 (November 5, 2021): 2751. http://dx.doi.org/10.1182/blood-2021-150998.
Full textLentzsch, Suzanne, Brea Lipe, Sascha A. Tuchman, Nizar J. Bahlis, William I. Bensinger, Michael Sebag, Heather J. Sutherland, et al. "Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)." Blood 138, Supplement 1 (November 5, 2021): 1651. http://dx.doi.org/10.1182/blood-2021-150232.
Full textRoose, Elien, An-Sofie Schelpe, Edwige Tellier, György Sinkovits, Gilles Kaplanski, Maelle Le Besnerais, Ilaria Mancini, et al. "Open ADAMTS13 Conformation in Immune-Mediated Thrombotic Thrombocytopenic Purpura Is Induced By Anti-ADAMTS13 Autoantibodies and Corresponds with an Ongoing ADAMTS13 Pathology." Blood 132, Supplement 1 (November 29, 2018): 222. http://dx.doi.org/10.1182/blood-2018-99-113762.
Full textStein, Eytan M., Courtney D. DiNardo, Amir T. Fathi, Alice S. Mims, Michael R. Savona, Anthony S. Stein, Richard M. Stone, et al. "Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation." Blood 138, Supplement 1 (November 5, 2021): 1276. http://dx.doi.org/10.1182/blood-2021-146507.
Full textPeyvandi, Flora, Bruce A. Schwartz, and Sigurd Knaub. "Efficacy and Pharmacokinetics of a New Fibrinogen Concentrate in Treating Acute Bleeding in Adolescent Patients with Congenital Fibrinogen Deficiency." Blood 132, Supplement 1 (November 29, 2018): 2501. http://dx.doi.org/10.1182/blood-2018-99-116572.
Full textJurczak, Wojciech, Caroline Dartigeas, Marta Coscia, Peter S. Ganly, Ghassan Al-Jazayrly, Chunxiao Wang, Katherine Bao, Ching Ching Leow, Safi Shahda, and Pier Luigi Zinzani. "BRUIN CLL-313: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)." Blood 138, Supplement 1 (November 5, 2021): 3732. http://dx.doi.org/10.1182/blood-2021-145938.
Full textCarlo-Stella, Carmelo, Pier Luigi Luigi Zinzani, Anna Sureda, Luís Francisco Araújo, Olivier Casasnovas, Cecilia Carpio, Su-Peng Yeh, et al. "A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma." Blood 138, Supplement 1 (November 5, 2021): 4362. http://dx.doi.org/10.1182/blood-2021-148431.
Full textJurczak, Wojciech, Pier Luigi Zinzani, Georg Hess, Gianluca Gaidano, Mariano Provencio, Zsolt Nagy, Tadeusz Robak, et al. "A Phase IIa, Open-Label, Multicenter Study of Single-Agent Tafasitamab (MOR208), an Fc-Optimized Anti-CD19 Antibody, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma: Long-Term Follow-up, Final Analysis." Blood 134, Supplement_1 (November 13, 2019): 4078. http://dx.doi.org/10.1182/blood-2019-124297.
Full textPeyvandi, Flora, Bruce A. Schwartz, and Sigurd Knaub. "Efficacy and Safety of Fibrinogen Concentrate for on-Demand Treatment of Acute Bleeding and for Surgical Prophylaxis in Subjects with Congenital Fibrinogen Deficiency — a Phase 3 Study." Blood 132, Supplement 1 (November 29, 2018): 2502. http://dx.doi.org/10.1182/blood-2018-99-116440.
Full textKornauth, Christoph, Tea Pemovska, Gregory Ian Vladimer, Günther Bayer, Michael Bergmann, Sandra Eder, Ruth Eichner, et al. "Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial." Blood 136, Supplement 1 (November 5, 2020): 2–4. http://dx.doi.org/10.1182/blood-2020-140831.
Full textYoung, Guy, Robert F. Sidonio, Ri Liesner, Johannes Oldenburg, Tiffany Chang, Marianne Uguen, Christophe Dhalluin, et al. "HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors." Blood 130, Suppl_1 (December 7, 2017): 85. http://dx.doi.org/10.1182/blood.v130.suppl_1.85.85.
Full textOldenburg, Johannes, María Teresa Alvarez Román, Giancarlo Castaman, Maissaa Janbain, Tadashi Matsushita, Karina Meijer, Sabine Friedl, Martin Sanabria, and Mark Reding. "Real-World Effectiveness and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) in Previously Treated Patients with Hemophilia A (HEM-POWR): Online Patient Portal and LIFE-ACTIVE Sub-Study." Blood 134, Supplement_1 (November 13, 2019): 4943. http://dx.doi.org/10.1182/blood-2019-128140.
Full textMiesbach, Wolfgang A., Giovanni Di Minno, Elena Santagostino, Dr Klamroth, Inga Bayh, Amaryllis Soto, and Cedric Hermans. "Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) Prophylaxis in Patients with Severe Hemophilia a and Comorbidities: A Post Hoc Analysis of PROTECT VIII Data." Blood 134, Supplement_1 (November 13, 2019): 1117. http://dx.doi.org/10.1182/blood-2019-128486.
Full textKojima, S., T. Iwamoto, Y. Kobayashi, M. Kato, F. Takizawa, T. Ida, Y. Toda, et al. "POS0572 IMMUNOGENICITY AND SAFETY OF ADJUVANTED RECOMBINANT ZOSTER VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS." Annals of the Rheumatic Diseases 82, Suppl 1 (May 30, 2023): 554.2–555. http://dx.doi.org/10.1136/annrheumdis-2023-eular.1608.
Full textPeyvandi, Flora, Spero R. Cataland, Marie Scully, Paul Coppo, Paul Knöbl, Johanna A. Kremer Hovinga, Ara Metjian, et al. "Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura." Blood 132, Supplement 1 (November 29, 2018): 373. http://dx.doi.org/10.1182/blood-2018-99-112125.
Full textRaje, Noopur, Paul Richardson, Parameswaran N. Hari, Anuj Mahindra, Sarah Kaster, Christine Connolly, Linda Rivera, et al. "An Open-Label Phase I Study of the Safety and Efficacy of RAD001 in Combination with Lenalidomide in the Treatment of Patients with Relapsed and Relapsed/Refractory Multiple Myeloma." Blood 114, no. 22 (November 20, 2009): 3856. http://dx.doi.org/10.1182/blood.v114.22.3856.3856.
Full textChavez, Julio C., Neta Goldschmidt, Felipe Samaniego, Tomasz Wrobel, Federica Cavallo, Gustavo Fonseca, Sung-Soo Yoon, et al. "The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial." Blood 138, Supplement 1 (November 5, 2021): 45. http://dx.doi.org/10.1182/blood-2021-147425.
Full textNoy, Ariela, Sven de Vos, Catherine Thieblemont, Peter Martin, Christopher Flowers, Franck Morschhauser, Graham P. Collins, et al. "Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study." Blood 128, no. 22 (December 2, 2016): 1213. http://dx.doi.org/10.1182/blood.v128.22.1213.1213.
Full textKremer Hovinga, Johanna A., Marie Scully, Spero R. Cataland, Flora Peyvandi, Paul Coppo, Paul Knöbl, Javier De La Rubia, et al. "Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study." Blood 132, Supplement 1 (November 29, 2018): 3744. http://dx.doi.org/10.1182/blood-2018-99-112177.
Full textSiegel, David S., Gary J. Schiller, Christy J. Samaras, Michael Sebag, Jesus G. Berdeja, Siddhartha Ganguly, Jeffrey V. Matous, et al. "Pomalidomide, Dexamethasone, and Daratumumab after Lenalidomide Treatment in Relapsed Refractory Multiple Myeloma: Updated Results from an Open-Label, Multicenter, Phase 2 Trial." Blood 136, Supplement 1 (November 5, 2020): 16–17. http://dx.doi.org/10.1182/blood-2020-134189.
Full textDreyling, Martin, Panayiotis Panayiotidis, George A. Follows, Luigina Mollica, Arnon Nagler, Muhit Özcan, Armando Santoro, et al. "Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma." Blood 134, Supplement_1 (November 13, 2019): 1531. http://dx.doi.org/10.1182/blood-2019-121932.
Full textPerkins, Andrew Charles, Kate Burbury, Thomas Lehmann, David M. Ross, Andreas Reiter, Vikas Gupta, Claire Harrison, et al. "Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis." Blood 136, Supplement 1 (November 5, 2020): 52–53. http://dx.doi.org/10.1182/blood-2020-140408.
Full textZinzani, Pier Luigi, Armando Santoro, Luigina Mollica, Sirpa Leppä, George A. Follows, Georg Lenz, Won Seog Kim, et al. "Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies." Blood 134, Supplement_1 (November 13, 2019): 4009. http://dx.doi.org/10.1182/blood-2019-131779.
Full textDadwal, Sanjeet S., Michael Shuster, Gary Douglas Myers, Keith Boundy, Marshelle Warren, Elizabeth Stoner, Thuy Truong, and Joshua A. Hill. "Posoleucel (ALVR105), an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Viral Infections Post-HCT: Results from an Open-Label Cohort of a Phase 2 Trial." Blood 138, Supplement 1 (November 5, 2021): 1760. http://dx.doi.org/10.1182/blood-2021-152553.
Full textPaschka, Peter, Hervé Dombret, Xavier Thomas, Christian Recher, Sylvain Chantepie, Pau Montesinos Fernandez, Evelyn Acuña-Cruz, et al. "Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls." Blood 136, Supplement 1 (November 5, 2020): 18–19. http://dx.doi.org/10.1182/blood-2020-136957.
Full textKumagai, Takashi, Kazunori Murai, Hiroshi Ureshino, Hideo Tanaka, Kaichi Nishiwaki, Satoshi Wakita, Koiti Inokuchi, et al. "Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial." Blood 138, Supplement 1 (November 5, 2021): 3601. http://dx.doi.org/10.1182/blood-2021-149483.
Full textStilgenbauer, Stephan, Francesc Bosch, Véronique Leblond, Osman Ilhan, Jens Kisro, Béatrice Mahé, Eva Mikuskova, et al. "Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy." Blood 134, Supplement_1 (November 13, 2019): 3035. http://dx.doi.org/10.1182/blood-2019-123419.
Full textShapiro, Amy, Giancarlo Castaman, Katarina Cepo, Lone Hvitfeldt Poulsen, Christian Hollensen, Tadashi Matsushita, Guy Young, Silva Zupancic-Salek, and Victor Jimenez-Yuste. "Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial." Blood 134, Supplement_1 (November 13, 2019): 1139. http://dx.doi.org/10.1182/blood-2019-122809.
Full textJurczak, Wojciech, Pier Luigi Luigi Zinzani, David Cunningham, Michel Azoulay, Wenying Huang, Weiming Xu, and Vincent Ribrag. "Coastal: A Phase 3 Study of the PI3Kδ Inhibitor Zandelisib with Rituximab (R) Versus Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)." Blood 138, Supplement 1 (November 5, 2021): 2430. http://dx.doi.org/10.1182/blood-2021-148015.
Full textMato, Anthony R., William G. Wierda, John M. Pagel, Matthew S. Davids, Pier Luigi Zinzani, Yi Lu, Hui Liu, et al. "BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)." Blood 138, Supplement 1 (November 5, 2021): 3742. http://dx.doi.org/10.1182/blood-2021-145936.
Full textUsmani, Saad Z., Maria-Victoria Mateos, Hareth Nahi, Sebastian Grosicki, Vladimir I. Vorobyev, Ivan Spicka, Vania T. M. Hungria, et al. "Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update." Blood 134, Supplement_1 (November 13, 2019): 1865. http://dx.doi.org/10.1182/blood-2019-122765.
Full textMatsumura, Itaru, Shigeki Ohtake, Yoshiko Atsuta, Mio Kurata, Yosuke Minami, Naoto Takahashi, Chiaki Nakaseko, et al. "Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212." Blood 136, Supplement 1 (November 5, 2020): 40–41. http://dx.doi.org/10.1182/blood-2020-134168.
Full textHampton, Kingsley, Pratima Chowdary, Scott Dunkley, Silke Ehrenforth, Lotte Jacobsen, Anne T. Neff, Elena Santagostino, et al. "First Report on the Safety and Efficacy of a Long-Acting Recombinant FVIII (turoctocog alfa pegol, N8-GP) during Major Surgery in Patients with Severe Hemophilia a." Blood 126, no. 23 (December 3, 2015): 2283. http://dx.doi.org/10.1182/blood.v126.23.2283.2283.
Full textNeelapu, Sattva S., Mohamed A. Kharfan-Dabaja, Olalekan O. Oluwole, Patel Krish, Ran Reshef, Peter A. Riedell, Parveen Shiraz, et al. "A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14)." Blood 134, Supplement_1 (November 13, 2019): 4093. http://dx.doi.org/10.1182/blood-2019-126369.
Full textBailey, Neil, Tenzin Tsomo, Jennie Szeto, William I. Bensinger, Daniel Egan, Livia Hegerova, Raya Mawad, et al. "Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma." Blood 136, Supplement 1 (November 5, 2020): 34. http://dx.doi.org/10.1182/blood-2020-141074.
Full textElsawy, Mahmoud, Julio C. Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, et al. "Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)." Blood 138, Supplement 1 (November 5, 2021): 430. http://dx.doi.org/10.1182/blood-2021-147598.
Full textStewart, A. Keith, S. Vincent Rajkumar, Meletios A. Dimopoulos, Tamás Masszi, Ivan Spicka, Albert Oriol, Roman Hájek, et al. "Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide and Dexamethasone in Patients (Pts) with Relapsed Multiple Myeloma: Interim Results from ASPIRE, a Randomized, Open-Label, Multicenter Phase 3 Study." Blood 124, no. 21 (December 6, 2014): 79. http://dx.doi.org/10.1182/blood.v124.21.79.79.
Full textBussel, James B., Francesco Rodeghiero, Roger M. Lyons, Barry Firstenberg, Joanne Joseph, Craig M. Kessler, Louis Terriou, Roberto Stasi, Paul Chang, and Susie Jun. "Sustained Hemostatic Platelet Counts in Adults with Immune Thrombocytopenia (ITP) Following Cessation of Treatment with the TPO Receptor Agonist Romiplostim: Report of 9 Cases,." Blood 118, no. 21 (November 18, 2011): 3281. http://dx.doi.org/10.1182/blood.v118.21.3281.3281.
Full textZinzani, Pier Luigi, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A. Reeves, Wanda Knopinska-Posluszny, et al. "Umbralisib, the Once Daily Dual Inhibitor of PI3Kδ and Casein Kinase-1ε Demonstrates Clinical Activity in Patients with Relapsed or Refractory Indolent Non-Hodgkin Lymphoma: Results from the Phase 2 Global Unity-NHL Trial." Blood 136, Supplement 1 (November 5, 2020): 34–35. http://dx.doi.org/10.1182/blood-2020-134851.
Full textVannucchi, Alessandro M., Heinz Gisslinger, Claire N. Harrison, Haifa Kathrin Al-Ali, Ester Pungolino, Jean-Jacques Kiladjian, Francoise Boyer-Perrard, et al. "EXPAND: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib in Patients with Myelofibrosis (MF) and Low Platelet Counts (50 × 109/L to 99 × 109/L) at Baseline." Blood 126, no. 23 (December 3, 2015): 2817. http://dx.doi.org/10.1182/blood.v126.23.2817.2817.
Full textSantagostino, Elena, Kathelijn Fischer, Christoph Koenigs, Claudia Djambas Khayat, Samantha Lucas, Blanca Salazar, Andres Brainsky, Thomas Chung, Brahm Goldstein, and Johnny Mahlangu. "Interim Analysis of the Extension Study with rVIII-SingleChain in Previously Untreated Patients (PUPs) with Severe Hemophilia A (CSL627-3001)." Blood 134, Supplement_1 (November 13, 2019): 162. http://dx.doi.org/10.1182/blood-2019-123981.
Full textLonial, Sagar, Stefano R. Tarantolo, Ralph V. Boccia, Habte Yimer, Moshe Y. Levy, Rafat Abonour, Meera Mohan, et al. "Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma." Blood 138, Supplement 1 (November 5, 2021): 2742. http://dx.doi.org/10.1182/blood-2021-148385.
Full textChiaretti, Sabina, Renato Bassan, Antonella Vitale, Loredana Elia, Alfonso Piciocchi, Cristina Puzzolo, Martina Canichella, et al. "Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph+ ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial." Blood 134, Supplement_1 (November 13, 2019): 740. http://dx.doi.org/10.1182/blood-2019-128759.
Full textDucore, Jonathan M., Shadan Lalezari, Elena Santagostino, Sanjay P. Ahuja, Monika Maas Enriquez, Claudia Tueckmantel, and Mark Reding. "Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study." Blood 134, Supplement_1 (November 13, 2019): 1129. http://dx.doi.org/10.1182/blood-2019-123947.
Full textJimenez-Yuste, Victor, Midori Shima, Katsuyuki Fukutake, Michaela Lehle, Sammy Chebon, Sylvie Retout, Agnès Portron, and Gallia G. Levy. "Emicizumab Subcutaneous Dosing Every 4 Weeks for the Management of Hemophilia A: Preliminary Data from the Pharmacokinetic Run-in Cohort of a Multicenter, Open-Label, Phase 3 Study (HAVEN 4)." Blood 130, Suppl_1 (December 7, 2017): 86. http://dx.doi.org/10.1182/blood.v130.suppl_1.86.86.
Full textMackensen, Andreas, Linda Hanssens, Matthias Stelljes, Wolfgang A. Bethge, Tobias Feuchtinger, Annette Künkele, Michael Aigner, et al. "A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts." Blood 138, Supplement 1 (November 5, 2021): 3836. http://dx.doi.org/10.1182/blood-2021-152452.
Full textZinzani, Pier Luigi, Vincent Delwail, Shankara Paneesha, Simon Rule, Alejandro Martin Garcia-Sancho, Ana Marin-Niebla, Gilles Salles, et al. "Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)." Blood 136, Supplement 1 (November 5, 2020): 43–44. http://dx.doi.org/10.1182/blood-2020-134609.
Full textÁlvarez Roman, Teresa, Elena Monzón Manzano, Ihosvany Fernandez-Bello, Mónica Martín, María Isabel Rivas Pollmar, Raul Justo Sanz, Sara García Barcenilla, et al. "Real Life Experience in Clinical Practice with Recombinant Coagulation FVIII-Fc Fusion Protein." Blood 134, Supplement_1 (November 13, 2019): 4929. http://dx.doi.org/10.1182/blood-2019-127878.
Full textMehta, Amitkumar, Marek Trněný, Jan Walewski, Vincent Ribrag, Caroline Dartigeas, Jacob Haaber Christensen, Fabrizio Pane, et al. "Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205)." Blood 136, Supplement 1 (November 5, 2020): 22–23. http://dx.doi.org/10.1182/blood-2020-134872.
Full text